Male breast cancer: Austrian experience.

Stierer, M; Rosen, H; Weitensfelder, W; Hausmaninger, H; Teleky, B; Jakesz, R; Fruhwirth, H; Dünser, M; Beller, S; Haid, A; World J Surg. 1995; 19(5): 687-692.

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

Villunger, A; Egle, A; Kos, M; Hittmair, A; Maly, K; Greil, R; Int J Cancer. 1996; 65(4):498-505

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle, A; Villunger, A; Kos, M; Böck, G; Gruber, J; Auer, B; Greil, R; Eur J Immunol. 1996; 26(12): 3119-3126.

2″,2″-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

Gruber, J; Geisen, F; Sgonc, R; Egle, A; Villunger, A; Boeck, G; Konwalinka, G; Greil, R; Stem Cells. 1996; 14(3):351-362

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

Fridrik, MA; Hausmaninger, H; Linkesch, W; Stöger, M; Sill, H; Neubauer, M; Seewann, HL; Klocker, J; Haidinger, R; Schiller, L; Pont, J; Raudaschl, G; Falk, M; Radaszkiewicz, T; J Clin Oncol. 1996; 14(1): 227-232.

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Egle, A; Marschitz, I; Posch, B; Herold, M; Greil, R; Br J Haematol. 1996; 94(1):211-212

Fas (Apo-1/CD95) – Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.

Greil, R; Villunger, A; Egle, A; Marschitz, L; Kos, M; Bock, G; Ludwig, H; Geley, S; Kofler, R BLOOD. 1997; 90(10): 1578-1578.

Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.

Prior, C; Oroszy, S; Oberaigner, W; Schenk, E; Kummer, F; Aigner, K; Hausmaninger, H; Peschel, C; Huber, H; Eur Respir J. 1997; 10(2): 392-396.

Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

Villunger, A; Egle, A; Marschitz, I; Kos, M; Böck, G; Ludwig, H; Geley, S; Kofler, R; Greil, R; BLOOD. 1997; 90(1): 12-20.

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle, A; Villunger, A; Marschitz, I; Kos, M; Hittmair, A; Lukas, P; Grünewald, K; Greil, R; BRIT J HAEMATOL. 1997; 97(2): 41-28.